The FINANCIAL -- Daiichi Sankyo Company, Limited (TSE: 4568), announced on October 29 that it submitted an application in Japan on October 28 to manufacture and market an injectable preparation of Levofloxacin Hydrate that incorporates the company's new quinolone anti-bacterial agent.

Clinical trials have confirmed the injection's excellent clinical efficacy against pneumonia and secondary chronic respiratory infections. Cravit, an oral Levofloxacin Hydrate agent, already is a widely accepted treatment in formulations of 500mg and 250mg tablets and as a 10% fine granular preparation. The addition of an injectable version in Levofloxacin Hydrate lineup would contribute further to infectious disease treatment.

Related Stories

• U.S. Food and Drug Administration Approves ABILIFY (aripiprazole)
• AZN and the Philadelphia Department of Public Health provide free medicines to Pennsylvania’s uninsu
• European medical advisory committee does not recommend approval of Avastin